Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
russian-backbone seasonal trivalent live attenuated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
A Russian-backbone seasonal trivalent live attenuated influenza vaccine (LAIV) is an intranasal vaccine designed to protect against three strains of seasonal influenza. It uses a cold-adapted, temperature-sensitive Russian master donor virus backbone to deliver live but weakened forms of the selected circulating influenza A and B viruses. The primary mechanism is induction of mucosal and systemic immune responses by limited replication in the upper respiratory tract without causing disease. This LAIV has been developed as an affordable and logistically feasible option for mass immunization programs in children and adults in low- and middle-income countries. The main developers are NPO Microgen (Russia) and Serum Institute of India; it is marketed under brand names such as Nasovac-S (India) and Ultravac (Russia). Clinical trials have demonstrated its safety, immunogenicity, and ability to induce both humoral and cellular immunity[1][2][3].
- Brand names
- nasovac-sultravac
- Other names
- live attenuated influenza vaccine (russian backbone)nasovacultravac-s
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on russian-backbone seasonal trivalent live attenuated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on russian-backbone seasonal trivalent live attenuated influenza vaccine.